Related Experiment Video
Updated: Mar 6, 2026

Homogeneous Glycoconjugate Produced by Combined Unnatural Amino Acid Incorporation and Click-Chemistry for Vaccine Purposes
Published on: December 19, 2020
Biosynthesis of a Polysaccharide-based Glycoconjugate Vaccine against Neonatal Meningitis-Causing Escherichia coli
Yuhui Wang1,2,3,4, Haodi Liu1,2,3,4, Yahao Wang1,2,3,4
1National Glycoengineering Research Center, Shandong University, Qingdao, Shandong 266237, China.
Abstract:
Extraintestinal pathogenic Escherichia coli O45 is an emerging multidrug-resistant serotype. Herein, we developed a glycoengineered E. coli strain for efficient biosynthesis of O45 O-polysaccharide (OPS45) and the OPS45-based glycoconjugate vaccine. Systematic optimization enhanced the production of OPS45, a polysaccharide containing the rare sugars 6-deoxy-l-talose (6d-l-Tal) and N-acetylfucosamine (FucNAc), with structure confirmed by NMR. Using oligosaccharyltransferase-mediated conjugation in this glyco-optimized chassis strain, we generated a homogeneous cholera toxin B subunit (CTB)-OPS45 glycoconjugate with enhanced antigen loading yield (11.31 ± 0.59 mg/L vs 8.24 ± 0.075 mg/L). LC-MS/MS verified site-specific glycosylation on CTB. Immunization in mice elicited strong O45-specific IgG responses and conferred 90% protection against lethal neonatal meningitis-causing Escherichia coli (NMEC) infection, with a nearly 80% reduction in bacterial burden. These results demonstrate that our integrated biosynthesis and conjugation approach enables rapid and efficient production of a well-defined glycoconjugate vaccine, showing strong potential for combatting resistant NMEC and O45 infections.
Insights
A novel glycoengineered Escherichia coli strain efficiently produces O45 O-polysaccharide for a glycoconjugate vaccine. This vaccine shows high protection against neonatal meningitis-causing E. coli (NMEC) infections.
Area of Science:
- Microbiology
- Glycobiology
- Vaccine Development
Background:
- Extraintestinal pathogenic Escherichia coli O45 (O45) is a growing multidrug-resistant threat.
- Neonatal meningitis-causing E. coli (NMEC) poses a significant public health challenge.
Purpose of the Study:
- To develop a glycoengineered E. coli strain for efficient biosynthesis of O45 O-polysaccharide (OPS45).
- To create an OPS45-based glycoconjugate vaccine for protection against NMEC infections.
Main Methods:
- Glycoengineering of E. coli for enhanced OPS45 production, including rare sugars 6-deoxy-l-talose and N-acetylfucosamine.
- Oligosaccharyltransferase-mediated conjugation of OPS45 to cholera toxin B subunit (CTB).
- Structural confirmation of OPS45 using NMR and LC-MS/MS analysis of the CTB-OPS45 conjugate.
Main Results:
- Optimized OPS45 production in the glycoengineered E. coli strain.
- Generation of a homogeneous CTB-OPS45 glycoconjugate with improved antigen loading (11.31 ± 0.59 mg/L).
- Immunization in mice induced strong O45-specific IgG responses and provided 90% protection against lethal NMEC infection.
Conclusions:
- The integrated biosynthesis and conjugation approach enables rapid, efficient production of a well-defined glycoconjugate vaccine.
- The developed vaccine demonstrates significant potential for combating resistant NMEC and O45 infections.
- This strategy offers a promising platform for developing vaccines against other challenging bacterial pathogens.
More Related Videos
Related Concept Videos
Oligosaccharide Assembly
Multiple sugar molecules that may or may...
Formation of Lipopolysaccharides
Biosynthesis of Polysaccharides
Protein Glycosylation
Glycosylation occurs in...
Peptidoglycan Synthesis
Conjugated Proteins
Nucleoproteins are protein complexes that contain nucleic acids, categorized as deoxyribonucleoproteins (DNPs) or ribonucleoproteins (RNPs) respectively. The nucleosome is a typical example of a DNP where nuclear DNA is associated with histone proteins. The major antigen for the Covid-19 virus SARS-CoV is an RNP that is critical...

